Motexafin gadolinium (MGd) overcomes adverse survival effect of anemia in brain metastases (BM) patients treated with whole brain radiation therapy (WBRT): analysis of a phase III randomized trial Article

Kumar, P, Mehta, MP, Rodrigus, P et al. (2003). Motexafin gadolinium (MGd) overcomes adverse survival effect of anemia in brain metastases (BM) patients treated with whole brain radiation therapy (WBRT): analysis of a phase III randomized trial . INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 57(2), s133. 10.1016/s0360-3016(03)00838-1

cited authors

  • Kumar, P; Mehta, MP; Rodrigus, P; Suh, J; Sagar, S; Kunkler, I; Carrie, C; Smith, JA; Phan, S; Renschler, MF

authors

publication date

  • October 1, 2003

published in

keywords

  • 32 Biomedical and Clinical Sciences
  • 3211 Oncology and Carcinogenesis

Digital Object Identifier (DOI)

publisher

  • Elsevier

start page

  • s133

volume

  • 57

issue

  • 2